Cipher Pharmaceuticals Q3 2026 results show net revenue of $12.7 million, net income of $10.9 million, Epuris sales up 15% and Natroba up 14% sequentially, plus a $5.7 million arbitration collection.
Merck KGaA Q3 2026 results show 5.1% organic sales growth to €5.6 billion, strong Process Solutions and Rare Diseases performance, the Pimjetmi FDA approval, and a raised full-year 2026 outlook.
Novo Nordisk has committed USD 200 million over ten years (2027–2036) to the World Diabetes Foundation to strengthen diabetes prevention and care in low- and middle-income countries, announced ahead of World Diabetes Day.
Charles River Laboratories (NYSE: CRL) has agreed to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania for about $470 million in cash, plus up to $75 million in contingent payments. Closing is expected in the first half of 2027.
Eli Lilly vs Novo Nordisk Q3 2026: Lilly revenue rose 39% to $24.4 billion on Mounjaro and Zepbound, while Novo Nordisk adjusted sales grew 4% at CER. Both raised 2026 guidance. See the side-by-side data.
Novo Nordisk Q3 2026 results show Wegovy pill sales of DKK 5,394 million, adjusted operating profit up 27% at constant exchange rates, and a raised 2026 outlook. The report also covers CagriSema data, DKK 8.7 billion of impairments and a CFO change.
Pfizer Q3 2026 Results show $16.6 billion in revenue, 32% operational growth from launched and acquired products, and a raised 2026 outlook of $62.0–$64.0 billion. Pfizer also named Cecile Guegan as CFO and reported progress for Elrexfio, Litfulo, Talzenna and Tukysa.
Merck KGaA has signed a definitive agreement to divest its CDMO business to Lonza for a mid-triple-digit million-euro amount. The deal covers five US-based operations and is expected to close in mid-2027.
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology led growth, the company reconfirmed FY2026 guidance, and it reported 12 positive Phase III programme readouts.
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase.
